Related Experiment Videos
Transgenic mouse model for skin malignant melanoma
M Kato1, M Takahashi, A A Akhand
1Department of Immunology, Nagoya University School of Medicine, Japan.
Oncogene
|October 20, 1998
Summary
A novel mouse model with metallothionein-I (MT)/ret transgene develops stepwise skin melanosis, benign tumors, and malignant melanoma. Increased ret transgene expression correlates with tumor progression and metastasis, suggesting its role in malignant transformation.
Area of Science:
- Oncology
- Genetics
- Dermatology
Background:
- Giant congenital melanocytic nevi are present at birth and can progress to malignant melanoma.
- Understanding the genetic and molecular mechanisms underlying melanoma development is crucial.
Purpose of the Study:
- To establish and characterize a novel metallothionein-I (MT)/ret transgenic mouse line for studying melanocytic tumor development.
- To investigate the role of the ret transgene in the stepwise progression of melanocytic tumors to malignant melanoma.
Main Methods:
- Generation of a novel MT/ret transgenic mouse line.
- Stepwise analysis of skin melanosis, benign melanocytic tumors, and malignant melanoma development.
- Monitoring of ret transgene expression levels and activity.
- Assessment of mitogen-activated protein kinases (MAPKs), c-Jun, and matrix metalloproteinases activation.
Main Results:
- The MT/ret transgenic mice exhibited a stepwise development of skin melanosis, benign melanocytic tumors, and metastatic malignant melanoma.
- Ret transgene expression and activity increased progressively during tumor development.
- Increased ret transgene expression correlated with the activation of MAPKs, c-Jun, and matrix metalloproteinases.
Conclusions:
- Progressive dysregulation of ret transgene expression is implicated in the malignant transformation of melanocytic tumors in this mouse model.
- This MT/ret transgenic mouse line serves as a valuable model for studying human giant congenital melanocytic nevi and melanoma progression.